Cargando…
Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
Interferon (IFN) has been highlighted in several randomized controlled trials as an attractive therapeutic candidate based plausible mode of action, suppressed response in severe COVID-19, and inhibition of SARS-CoV-2 replication. This study investigated the efficacy and safety of IFN in patients wi...
Autores principales: | Ryoo, Seungeun, Koh, Dae-Hyup, Yu, Su-Yeon, Choi, Miyoung, Huh, Kyungmin, Yeom, Joon-Sup, Heo, Jung Yeon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057835/ https://www.ncbi.nlm.nih.gov/pubmed/36989209 http://dx.doi.org/10.1371/journal.pone.0272826 |
Ejemplares similares
-
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022) -
Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2023) -
Type I and type III interferon in opposition?
por: Park, Matthew D.
Publicado: (2020) -
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
por: Kim, Sun Bean, et al.
Publicado: (2021) -
Differential Regulation of Type I and Type III Interferon Signaling
por: Stanifer, Megan L., et al.
Publicado: (2019)